⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
RANKL Inhibitors (Denosumab)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: Pragmatic randomized, double-blind, active-controlled trial launched to test RANKL inhibition for sarcopenia in hip fracture patients — protocol/objective stage, no efficacy readout yet. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
16-sep-2026
novelty 3
per-area 3
strengthens